These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
80 related articles for article (PubMed ID: 3263693)
1. On reference values for tumor markers in prostatic carcinoma. Lewenhaupt A; Ekman P; Eneroth P; Kallner A Scand J Urol Nephrol Suppl; 1988; 110():119-23. PubMed ID: 3263693 [TBL] [Abstract][Full Text] [Related]
2. Serum levels of prostatic acid phosphatase (PAP), tissue polypeptide antigen (TPA), CA-50, neopterine and of osteocalcin in patients with prostatic carcinoma. Lewenhaupt A; Ekman P; Eneroth P; Eriksson A; Nordström L Scand J Clin Lab Invest Suppl; 1985; 179():75-80. PubMed ID: 3878574 [No Abstract] [Full Text] [Related]
3. Aspects on reference values for tumor markers in human prostatic carcinoma. Ekman P; Lewenhaupt A; Eneroth P; Kallner A Am J Clin Oncol; 1988; 11 Suppl 2():S80-2. PubMed ID: 2468281 [TBL] [Abstract][Full Text] [Related]
4. [The clinical significance of serum tissue polypeptide antigen as a tumor marker for urogenital carcinomas--a comparison with other tumor markers in patients with renal cell carcinoma and prostatic carcinoma]. Yamazaki K; Kumamoto Y; Tsukamoto T; Umehara T; Ohmura K Hinyokika Kiyo; 1987 Oct; 33(10):1581-9. PubMed ID: 2451408 [TBL] [Abstract][Full Text] [Related]
5. Serial measurements of tissue polypeptide specific antigen (TPS), PSA, PAP and CEA serotest values in treated patients with primary and metastatic prostate cancer. Tarle M Anticancer Res; 1993; 13(3):769-77. PubMed ID: 7686362 [TBL] [Abstract][Full Text] [Related]
6. [The tumor markers CEA, TPA and CA 19-9 and ferritin and osteocalcin in follow-up studies in breast cancer]. Schatz C; von Lieven H; Mulders M; Rowold J; Stracke H; Müller H; Grebe SF; Schatz H Wien Klin Wochenschr; 1985 Dec; 97(23):873-9. PubMed ID: 3878042 [TBL] [Abstract][Full Text] [Related]
7. Tumor markers in human prostatic carcinoma. An optimation of reference values. Lewenhaupt A; Ekman P; Eneroth P; Kallner A Eur Urol; 1990; 17(1):7-11. PubMed ID: 2180721 [TBL] [Abstract][Full Text] [Related]
8. Correlation of cell proliferation marker (TPS), natural killer (NK) activity and tumor load serotest (PSA) in untreated and treated prostatic tumors. Tarle M; Kovacić K; Kastelan M Anticancer Res; 1993; 13(1):215-8. PubMed ID: 7682800 [TBL] [Abstract][Full Text] [Related]
9. Tumor markers. Consensus Conference on Diagnosis and Prognostic Parameters in Localized Prostate Cancer. Stockholm, Sweden, May 12-13, 1993. Stamey TA; Ekman PE; Blankenstein MA; Cooper EH; Kontturi M; Lilja H; Oesterling JE; Stenman UH; Turkes A Scand J Urol Nephrol Suppl; 1994; 162():73-87; discussion 115-27. PubMed ID: 7529430 [TBL] [Abstract][Full Text] [Related]
10. Clinical value of serum tumour markers TPA, TPS, TAG 12, CA 15-3 and MCA in breast cancer diagnosis; results from a prospective study. Eskelinen M; Hippeläinen M; Kettunen J; Salmela E; Penttilä I; Alhava E Anticancer Res; 1994; 14(2B):699-703. PubMed ID: 8010729 [TBL] [Abstract][Full Text] [Related]
11. [Value of neopterin as an oncologic laboratory parameter--observations in gynecologic tumors]. von Broen B; Kavungu P Z Gesamte Inn Med; 1990 Apr; 45(8):223-5. PubMed ID: 2378135 [TBL] [Abstract][Full Text] [Related]
12. The value of prostatic acid phosphatase and prostate specific antigen as serum markers in carcinoma of the prostate. Akdaş A; Simşek F; Ilker Y; Türkeri L; Ercan H Int Urol Nephrol; 1993; 25(3):271-8. PubMed ID: 7693607 [TBL] [Abstract][Full Text] [Related]
13. [Serum CA 125 and TPA determination in malignant neoplasms of the uterus]. Gadducci A; Facchini V; Bartolini T; Fioretti P Ann Ostet Ginecol Med Perinat; 1988; 109(3):151-5. PubMed ID: 3207319 [No Abstract] [Full Text] [Related]
14. Elevated serum levels of neopterin and soluble interleukin-2 receptor in patients with ovarian cancer. Gadducci A; Ferdeghini M; Malagnino G; Prontera C; Fanucchi A; Annicchiarico C; Bianchi R; Fioretti P; Facchini V Gynecol Oncol; 1994 Mar; 52(3):386-91. PubMed ID: 8157196 [TBL] [Abstract][Full Text] [Related]
15. Clinical evaluation of tissue polypeptide antigen (TPA) in the diagnosis of pancreatic carcinoma. Pasanen PA; Eskelinen M; Partanen K; Pikkarainen P; Penttila I Anticancer Res; 1993; 13(5C):1883-7. PubMed ID: 8267397 [TBL] [Abstract][Full Text] [Related]
16. The significance of neopterin determination as a tumour marker in ovarian cancer. Szarka G; Pulay T; Csömör S; Tran-Phoung-Mai ; Schumann B Acta Chir Hung; 1988; 29(4):359-64. PubMed ID: 3239335 [TBL] [Abstract][Full Text] [Related]
17. The use of CA-50 radioimmunoassay test in diagnosis of urologic malignancy. Tie for second place Jobst award. Hershman MJ; Habib NA; Ferro MA; Williamson RC; Wood CB Am Surg; 1987 Dec; 53(12):691-4. PubMed ID: 3480697 [TBL] [Abstract][Full Text] [Related]
18. Tissue polypeptide specific antigen and cancer associated serum antigen in the follow-up of ovarian cancer. Sliutz G; Tempfer C; Kainz C; Mustafa G; Gitsch G; Koelbl H; Biegelmayer C Anticancer Res; 1995; 15(3):1127-9. PubMed ID: 7645936 [TBL] [Abstract][Full Text] [Related]
19. CA 15-3, mucin-like carcinoma-associated antigen and tissue polypeptide-specific antigen: correlation to disease state and prognosis in breast cancer patients. Cohen AD; Gopas J; Karplus G; Cohen Y Isr J Med Sci; 1995; 31(2-3):155-9. PubMed ID: 7744585 [TBL] [Abstract][Full Text] [Related]
20. Tumour markers as prognostic aids in prostatic carcinoma. Lewenhaupt A; Ekman P; Eneroth P; Nilsson B Br J Urol; 1990 Aug; 66(2):182-7. PubMed ID: 1697204 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]